



**THE FOUNDATION
FOR SECURE
MARKETS**

#49014

Date: July 21, 2021

Subject: Alexion Pharmaceuticals, Inc. – Contract Adjustment
Option Symbol: 07/21/21 – ALXN remains ALXN
07/22/21 – ALXN becomes AZN1
Date: 07/21/21

On May 11, 2021, Shareholders of Alexion Pharmaceuticals, Inc. (ALXN) voted concerning the proposed merger with AstraZeneca PLC (AZN). The merger was approved and subsequently consummated before the open on July 21, 2021. As a result, each existing ALXN Common Share will be converted into the right to receive 2.1243 AZN American Depositary Shares, plus \$60.00 Cash. Cash will be paid in lieu of fractional AZN shares.

Contract Adjustment

Date: July 21, 2021

Option Symbol: 07/21/21 – ALXN remains ALXN (with adjusted deliverable described below)
07/22/21 – ALXN changes to AZN1

Strike Divisor: 1

Contracts Multiplier: 1

New Multiplier: 100 (e.g., a premium of 1.50 yields \$150; a strike of 170 yields \$17,000.00)

New Deliverable Per Contract:

- 1) 212 AstraZeneca PLC (AZN) American Depositary Shares
- 2) Cash in lieu of 0.43 fractional AZN American Depositary Shares
- 3) \$6,000.00 cash (\$60.00 x 100)

Note: Once determined, the cash in lieu of fractional share portion of the option deliverable will remain fixed and will not vary with price changes of any security.

CUSIP: AZN: 046353108

Pricing

Until the cash in lieu amount is determined, the underlying price for AZN1 will be determined as follows:

$$\text{AZN1} = 2.1243 (\text{AZN}) + 60.00$$

Delayed Settlement

The AZN component of the AZN1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the AZN1 deliverable until the cash in lieu of fractional AZN shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.